Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch"). GENova expects to generate licensing fees and royalties from the out-licensed manufacturing and marketing rights to leading pharmaceutical companies to exceed more than 5% in a market currently valued at $3billion+ a year over the following 15-20 years which is the duration of the patents.

Bridge BioResearch is an international drug discovery company that focuses on metabolic disorders, and has well-established distribution channels and relationships with leading pharmaceutical companies.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

The two companies are both in the business of acquiring early-stage developmental drugs, out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Bridge BioResearch specializes in Obesity and Type 2 Diabetes drugs. Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Big Pharma such as Biogen, Elan, Merck's and Genentech.

"This reciprocal arrangement is a huge benefit to both companies," says Aaron Whiteman, CEO for GENova. "I am confident that with our new access to Big Pharma distribution channels we can usher our promising patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen."


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... kidneys for transplantation. One solution is to increase the ... recent paper in the November issue of the journal ... strategies that have been developed to increase the number ... the adoption of these strategies at a single center. ...
... Italian epidemiologist as done a systematic review of various studies ... The study is focused to find out the link between ... believed that use of MMR vaccine shots in children’s may ... children around the world and concluded that MMR shots are ...
... characterized by progressive memory loss, decline in language skills ... to ageing population.// ,A recent paper in ... strategies in drug discovery. Hong-Yu Zhang, the author of ... one-drug-one-target strategy in drug discovery is limited, which has ...
... Acute ischemic stroke attributable to extracranial internal carotid artery ... death. // ,In selected cases, re-vascularization with carotid ... rate, and clinical outcomes in consecutive case series are ... a balloon-tipped catheter is inserted into an artery and ...
... Singh and Union Health Minister Anbumani Ramadoss are to convene ... problem of bird flu epidemic. //Awareness of bird flu and ... to the Western countries. The World Health Organization has sent ... if there are any possible flu attack. Dr. Anbumani said ...
... Professor Hans Theodor Eich and his colleagues from University ... radiation in Hodgkin’s Lymphoma patients undergoing chemotherapy does not ... reducing the side effects of radiation therapy. The results ... Therapeutic Radiology and Oncology. The researchers have reduced the ...
Cached Medicine News:Health News:Strategies To Boost Living Donor Kidney Transplants 2Health News:MMR Vaccination not linked to Autism 2
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional ... Toronto -based 3D visualization leader ... Congress of Neurological Surgeons Annual Meeting that they ... for brain surgery. The collaboration is the first ... combination to improve patient outcomes. NICO,s BrainPath® interventional ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho ... Co., Ltd. ( Japan ), announced ... granted Fast Track designation for TAS-102 (nonproprietary names: ... drug under investigation for the treatment of refractory ... has initiated a rolling NDA submission to the ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... treated with infliximab, a biologic therapy that has been used to ... diseases, including rheumatoid arthritis, Crohn,s disease and ulcerative colitis. , ... Human anti-chimeric antibody (HACA) ...
... May 13 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today it will be ... 2010 , at 8:45 a.m. Eastern Time .   , ... webcast of the presentation can be accessed via Zimmer,s Investor Relations website at http://investor.zimmer.com . ... , , About ...
Cached Medicine Technology:Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy 2Zimmer Holdings to Present at Baird's 2010 Growth Stock Conference 2
... addition to the Primus family of fine ... of speed and accuracy in a flexible ... testing. Test results in 2 minutes using ... lab or clinic., ,The PDQ system comes ...
Metrika's A1cNow Monitor is the first ever single-use test for hemoglobin A1c, it is the "gold standard" indicator of diabetes management. The test is easy to use, needs only a drop of blood and take...
... The intelligent CELL-DYN WorkCell delivers complete hematology ... operator safety. A modular configuration provides the ... basic system includes one Navigator module, one ... main bar code reader. The basic system ...
... The STart 4 semi-automated hemostasis ... of electro-mechanical clot detection (Viscosity-based Detection ... lipemic, icteric or other optically turbid ... analyzer offers programmable and preprogrammed assays ...
Medicine Products: